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Background
Human embryonic stem cells (hESCs) have two funda-
mental characteristics. First is pluripotency, they have the
ability to differentiate to all cell types of the three germ
layers endoderm, ectoderm and mesoderm in vitro (by
formation of embryoid bodies) and in vivo (by teratoma
formation in immune deficient mice). Second, hESCs
have the capability to self-renew indefinitely. Embryonic
stem cells express pluripotency-associated markers such
as OCT4, NANOG, SOX2, SSEA-4, TRA-1-60, TRA-1-
81 and alkaline phosphatase. The use of hESCs in
research and future regenerative medicine approaches is
hampered by ethical and moral concerns as these cells
are derived from blastocysts. Besides the derivation of
lineage-restricted cells from hESCs as well as the immune
rejection of hESCs derived cells are still problematic. To
avoid ethical and immune rejection concerns, scientists
searched for alternative ways to derive pluripotent cells
from mouse somatic cells [1]. Shortly after that two
groups managed reprogramming of human adult fibro-
blasts with viral transduction mediated over-expression
of four transcription factors OCT4, SOX2, KLF4 and c-
MYC or OCT4, SOX2, NANOG and LIN28. In general,
derivation of induced pluripotent stem cells (iPSCs) from
somatic cells and differentiating these into a donor cell
type of interest are promising approaches for (i) model-
ling human diseases in vitro, (ii) toxicology and drug
screening, (iii) future application in tissue replacement
therapies. We and others have shown that iPSCs can be
differentiated into hepatocyte-like cells that model in
vitro the patient’s genetic disease or metabolic capability,
thereby adding a further dimension to existing toxicity
testing platforms. An iPSC-based strategy thus allows
large scale studies impossible to perform on primary cell
cultures or from biopsies and also enables studies on
hepatocytes genetically susceptible to drug-induced liver
injury (DILI) as in vitro models with genotypic relevance
for toxicology screening. Furthermore, these patient-spe-
cific iPSC-derived hepatocytes can be used for character-
ising the metabolism of a candidate drug.
Materials and methods
Generation of cell types
The reprogramming of Human Foreskin Fibroblasts
(HFF1) was done as described by Yu et al. (2009) [2].
The hepatocyte-like cell (HLC) differentiation was
done as described by Jozefczuk et al. (2011) [3].
The generation of endoderm progenitor was done as
described by Cheng X. et al. (2012) [4].
Immunofluorescence-based detection of proteins
The cells were fixed with 4 % paraformaldehyde for
20 min at room temperature and washed two times with
PBS. Afterwards the cells were permeabilised with 0.1 %
Triton X-100 in PBS for 10 min. Subsequently, the cells
were blocked with a solution consisting of 10% fetal
bovine serum (Invitrogen), 0.1 % Triton X-100 (Sigma) in
PBS for 45 min. at room temperature. Next, the cells
were washed twice with PBS two times for 5 min. each at
room temperature. The primary antibody was diluted in
10 % fetal bovine serum (Invitrogen), 0.1 % Triton X-100
in PBS. The cells were covered with primary antibody
solution (1:200) using 400 μl per well of a 6 well culture
plate. The primary antibody was left on the cells for 1 h
at room temperature. Then the cells were washed as
described previously. The secondary antibody against the
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species in which the first antibody was produced, was
diluted 1:300 in 10 % fetal bovine serum (Invitrogen),
0.1 % Triton X-100 in PBS. The secondary antibody was
either conjugated to the dye Alexa Fluor 488 for green
fluorescence or to Alexa Fluor 594 for red fluorescence.
The diluted secondary antibody solution was added to
the cells using the same volume as for the primary anti-
body and was left on the cells for 1 h at room
Figure 1 Characterisation of induced pluripotent stem cells and the derived hepatocyte-like cells and endodermal progenitors. A: The
morphology of an E-iPSCs colony (left panel) and immunofluorescence-based detection of the expression of the pluripotency-specific protein
OCT4 (co-staining of nuclei with DAPI- right panel). B: Morphology of HLCs derived from E-iPSCs (left panel) and the expression of the mature
liver specific protein ALBUMIN (co-staining of nuclei with DAPI- right panel). C: Morphology of a representative endodermal progenitor colony
derived from E-iPSCs and cultured on mouse embryonic feeder cells (left panel). Expression of the self-renewal specific protein LGR5 (middle
panel), overlay of LGR5 expressing cells and DAPI stained cell nuclei (right panel). Scale bars 200μm.
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temperature in the dark followed by two washing steps
with PBS for 5 min each at room temperature. The nuclei
of the cells were counter-stained with 4´,6-Diamidin-2-
phenylindol (DAPI, 200 ng/ml, Invitrogen). 200 μl of
DAPI solution was added on the cells for 20 min at room
temperature. Finally, the cells were covered with PBS to
keep them moist. The fluorophores on the secondary
antibodies were visualised using a Zeiss, LSM 510 Meta
confocal microscope with a connected camera for micro-
scopy model AxioCam ICc3 and the software Axiovision
4.6. The following primary antibodies were used (dilution
1:200): Anti OCT4 mouse monoclonal (Santa Cruz), Anti
ALBUMIN mouse monoclonal (Sigma), Anti LGR5 rab-
bit polyclonal (Abgent) and the following secondary anti-
bodies were used (dilution 1:300): Alexa Fluor 594
conjugated goat anti-mouse IgG (H+L) (Invitrogen);
Alexa Fluor 488 conjugated donkey anti-rabbit IgG
(H+L) (Invitrogen).
Results
Derivation and characterisation of E-iPSCs
We derived episomal plasmid-based iPSCs (E-iPSCs)
from human fetal foreskin fibroblast cells (HFF1) as
described by Yu et al.[2]. E-iPSCs do not harbour exo-
genous DNA from the plasmid. These cells have a simi-
lar morphology to hESCs and express pluripotency
associated markers for example OCT4 (Figure 1a).
E-iPSCs are indeed pluripotent based on (i) embryoid
body formation in vitro, (ii) teratoma formation in vivo
and (iii) similar transcriptomes to hESCs (data not
shown).
Derivation and characterisation of hepatocyte-like cells
E-iPSCs were used to derive and characterize hepatocyte-
like cells (HLCs) as described in our earlier study, Jozefc-
zuk et al.[3]. The derived HLCs express the mature liver
specific protein ALBUMIN (Figure 1b) and a host of other
proteins such as alpha-fetoprotein (AFP), hepatocyte
nuclear factor 4 alpha (HNF4a), cytokeratin 18 (CK18),
bile salt export pump (BSEP) and sodium taurocholate
cotransporting polypeptide (NTCP) (data not shown).
Furthermore, we could detect glycogen storage, urea
secretion and CYP3A4 activity (data not shown).
Derivation and characterisation of endodermal pro-
genitors E-iPSCs were used to derive and characterize
endodermal progenitors following protocols described
by Cheng et al.[4] but with slight modifications. These
progenitor cells express the self-renewal marker leucine-
rich repeat containing G protein-coupled receptor 5
(LGR5) (Figure 1c) and also markers associated with the
foregut (SOX2), primitive gut (HNF4a), pancreas (pan-
creatic and duodenal homeobox 1, PDX1) and liver
(ALBUMIN) (data not shown).
Conclusions
In this study, we generated episomal-derived iPSCs (E-
iPSCs) and demonstrated that they are pluripotent both
in vitro and in vivo. These E-iPSCs are able to differenti-
ate into hepatocyte-like cells as well as endoderm pro-
genitors. Hepatocytes are the main cell type supporting
the detoxification function of the liver and as such they
are already extensively used for toxicology screens.
However, human primary hepatocytes cannot be
expanded in vitro and are difficult to obtain routinely or
in sufficient quantities. Human hepatocarcinoma-derived
and transformed, permanent cell lines, including HepG2,
THLE and HepaRG, have been used to meet the need
for liver cells, but their phenotypes diverge significantly
from normal primary hepatocytes. Accordingly, iPSC-
derived hepatocyte-like cells are seen as a potential
alternative to the currently used cell types. However,
prior to this, more rigorous comparative functionality
testing alongside freshly isolated primary hepatocytes is
needed. Further studies are planned involving the use of
the E-iPSCs derived endodermal progenitors to generate
hepatocyte-like cells and pancreatic-like cells. These stu-
dies will enable uncovering the genes and associated
pathways that specify a bipotential endodermal progeni-
tor to differentiate to either liver or pancreas. Addition-
ally, these E-iPSCs are a unique resource for disease
modelling, developmental studies, drug screening and
toxicology studies.
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